WO2005063270A1 - Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences - Google Patents

Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences Download PDF

Info

Publication number
WO2005063270A1
WO2005063270A1 PCT/EP2004/014458 EP2004014458W WO2005063270A1 WO 2005063270 A1 WO2005063270 A1 WO 2005063270A1 EP 2004014458 W EP2004014458 W EP 2004014458W WO 2005063270 A1 WO2005063270 A1 WO 2005063270A1
Authority
WO
WIPO (PCT)
Prior art keywords
red vine
vine leaves
aqueous extract
extract
composition according
Prior art date
Application number
PCT/EP2004/014458
Other languages
French (fr)
Inventor
Minoru Okada
Toshiaki Horie
Koichi Takahashi
Kenji Masuda
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Priority to BRPI0418293-6A priority Critical patent/BRPI0418293A/en
Priority to JP2006546018A priority patent/JP2007517785A/en
Priority to CA002548357A priority patent/CA2548357A1/en
Priority to EP04804059A priority patent/EP1708729A1/en
Priority to MXPA06007499A priority patent/MXPA06007499A/en
Publication of WO2005063270A1 publication Critical patent/WO2005063270A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • compositions comprising an effective dose of an aqueous extract of red vine leaves and a diuretic for preventing or alleviating mild-to-moderate chronic 10 venous insufficiency of the legs.
  • the composition according to this invention also includes acceptable pharmaceutical or dietetic additives.
  • the compositions according to this inventions decrease or prevent subjective symptoms such as lassitude (listlessness), heavy legs, tired legs, sensation of tension, and pain associated with swelling of calves and ankles due to disorder of leg venous flow. 15 2.
  • lassitude listlessness
  • heavy legs tired legs
  • sensation of tension and pain associated with swelling of calves and ankles due to disorder of leg venous flow.
  • CVI chronic venous insufficiency
  • oedema skin changes and subjective complaints such as tired, heavy legs, pain or tingling sensations, which are typically 25 amplified by standing upright and by high ambient temperatures. This dysfunction may be a source of major distress with a significant negative impact on the patient's overall well- being and quality of life.
  • grade I Early stages (grade I) are characterized by coronal phlebectasia paraplantaris, subfascial 30 congestion and oedema; grade II CVI is associated with low-grade skin changes, eczema and lipodermatosclerosis. If untreated, grades I and II often progress to an advanced stage characterized by recurrent venous leg ulcers (grade HI). The stress caused by the symptoms, even when relatively mild initially, and the risk of later complications call for appropriate supportive and preventive measures to be initiated in the early stages of CVI.
  • This extract of red vine leaves contains flavon (ol) -glycosides, -glucuronides and flavonoids, with quercetin-3-O-beta-D-glucuronide and isoquercitrin (quercetin-3-O-beta- glucoside) as its main active ingredients.
  • flavon (ol) -glycosides -glucuronides and flavonoids
  • quercetin-3-O-beta-D-glucuronide quercetin-3-O-beta-D-glucuronide
  • isoquercitrin quercetin-3-O-beta- glucoside
  • Dietary supplements including an aqueous extract of red vine leaves are disclosed to prevent and reduce the discomfort relating to mild-to-moderate chronic venous insufficiency of the legs in WO 01/28363.
  • compositions comprising an aqueous extract of red vine leaves and other active ingredients such as diuretics given by WO 01/28363.
  • this invention relates to new compositions that comprise an effective dose of an aqueous extract of red vine leaves and a diuretic as pharmacological active substances and their efficacies are potentiated for preventing and relaxing mild-to-moderate chronic venous insufficiency of the legs.
  • a primary objective of this invention provides more effective internal compositions for preventing and alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
  • a further objective of this invention provides more effective internal compositions including herb components and a diuretic.
  • the herb components were manufactured pursuant to a controlled process that preserves the herbal effectiveness of the ingredients for preventing and/or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
  • Another objective of this invention provides more effective internal compositions including herb components and a diuretic with minimum or no adverse event for safety of internal consumption that prevent and/or alleviate the discomfort associated with mild-to- moderate chronic venous insufficiency of the legs.
  • the other objective of this invention provides more effective internal pharmaceutical compositions and foods for preventing and/or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
  • This invention relates to internal compositions for preventing or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs including an effective dose of an aqueous extract of red vine leaves and a diuretic.
  • the internal composition of this invention consists of herbal ingredients derived from an aqueous extraction (Extractum vitis viniferae e folium spissum et siccum) of red vine leaves (folia vitis viniferae) and a diuretic.
  • the primary active ingredient of the internal composition is the aqueous extract of red vine leaves (foliae vitis viniferae L.).
  • aqueous extract of red vine leaves in this invention means the aqueous or solid aqueous extract of red vine leaves manufactured pursuant to a controlled process that preserves the herbal effectiveness of the ingredients.
  • dried extract of red vine leaves in this invention means dried pure extract of the above aqueous extract of red vine leaves.
  • red vine leaves extract in this invention means solid extracts added with silicon dioxide in the range of 1 to 10 (wt wt)% (described as %) and glucose syrup (as dried material) in the range of 5 to 25 % to the above dried extract of red vine leaves (solid pure extracts) in the range of 70 to 90 %.
  • Red vine leaves as starting material for the aqueous extract of red vine leaves in this invention is also known as "dyer" which are leaves of vitis vinifera LINNE with blackish- blue pericarp and a red pulp. Concentration of each polyphenol compound in red vine leaves and its composition are affected by various ecophysiological factors around. It is preferred that dried leaves of red vine containing at least 4 % of total polyphenols and 0.2 % of anthocyans are used as starting material in this invention. Red vine leaves characterized like those are harvested at a point of time where the content of flavonoids has reached an optimum i.e. around the harvesting time of the grapes. Moreover, less than 15 cm length and less than 12 cm width of red vine leaves are preferable.
  • the leaves are carefully dried and crushed.
  • For extraction the leaves are cut to pieces of preferably 5 to 10 mm.
  • the extraction is done using purified water at elevated temperature, preferably at a temperature in the range of 60 to 80 °C, over a time of at least 6 up to 10 hours.
  • the preferred method is that of an exhaustive percolation.
  • the so-called fluid extract obtained in the process of the extraction may be directly used in the preparation of liquid dosage forms.
  • at least a part of the solvent is removed by use of a suitable evaporator preferably.
  • the thick extract is sterilized under heated-compressed condition, preferably at a temperature from 120 to 150°C for 1 up to 30 seconds, more preferably at a temperature from 140 to 145°C for 2 up to 5 seconds.
  • the thick extract obtained in this step may again be directly used in the manufacturing of liquid dosage forms.
  • the thick extract is dried, for instance by use of a vacuum drying oven or a vacuum drying conveyer. Carriers or excipients may be added during drying to facilitate further processing of the extract.
  • the ratio of carriers or excipients in the range of 10 to 30 % and dried extract of red vine leaves (as pure extract) in the range of 70 to 90 % in red vine leaves extract is preferable.
  • Such carriers or excipients exemplify one or more than 2 kinds among silicon dioxide, maltodextrine, glucose syrup, cellulose and others. Silicon dioxide and glucose syrup are preferably used in this invention.
  • the ratio of silicon dioxide in the range of 1 to 10 %, glucose syrup (as dried) in the range of 5 to 25 % and dried extract of red vine leaves (as pure extract) in the range of 70 to 90 % in red vine leaves extract is preferable.
  • the ratio of silicon dioxide 2-5 %, glucose syrup (as dried) 10-20 % and dried extract of red vine leaves (as pure extract) 75-85 % in red vine leaves extract is more preferable.
  • the aqueous extract of red vine leaves used in this invention by pure extract conversion of an aqueous extract of red vine leaves contains total flavonoids (quercetin-3-O-beta-D- glucuronide) preferably in the range of 0.625 to 25 %, more preferably in the range of 1.25 to 12.5 %, specially in the range of 2.5 to 10 %.
  • This total flavonoid (quercetin-3-O-beta- D-glucuronide) content in red vine leaves extract (for example, a case in which dried extract of red vine leaves (as pure extract) 80 %) is preferable from 0.5 to 20 %, more preferable from 1 to 10 , special from 2 to 8 %.
  • the daily dosage of the aqueous extract of red vine leaves for an adult in equivalent quantity of dried extract of red vine leaves (pure extract) is usually from 64 to 800mg, preferably from 240 to 640 mg, more preferably from 280 to 600 mg and further more preferably 360 mg.
  • the daily dosage of the aqueous extract of red vine leaves for an adult in equivalent quantity of red vine leaves extract is usually from 80 to lOOOmg, preferably from 300 to 800 mg, more preferably 350 to 750 mg and further more preferably 450 mg.
  • compositions according to this invention include diuretics as second active ingredients in addition to above aqueous extract of red vine leaves.
  • Diuretics used in this invention are not limited and determined if the agents contain diuretic action, however, for safety of this agent with minimum or no adverse event, diuretics with mild effects used in non-prescription drug and health food field for many years are preferable. In addition, types and dosage of diuretics change depending on whether this internal composition is pharmaceutical products or not.
  • diuretics examples include aminophylline, caffeine, herb and crude drug having diuretics action, and diuretically efficient minerals.
  • caffeine group includes “caffeine and sodium benzoate", anhydrous caffeine, and caffeine etc.
  • examples of such crude drug and herb having diuretic action are poria sclerotium (Poria), akebia stem (Akebiae caulis), akebia fruit (Akebiae fructus), astragalus root (Astragali radix), alisma rhizome (Alismatis rhizoma), jujube (Zizyphi fructus), houttuynia herb (Houttuyniae herba), plantago seed (Plantaginis semen), plantago herb (Plantaginis herba), horsetail herb (Equiseti herb ⁇ ), gardenia fruit (Gardeniae fructus), nettle leaf (Urticae folium), nettle herb (Urticae herba), hibiscus rosell (Hibiscus sabdariffa), anemarrhena rhizome (Anemarrhenae rhizoma), motherwort herb (Leonuri herba), areca
  • Mnerals having diuretic efficacy are any sources of magnesium and potassium.
  • Minerals used in this invention are preferably water soluble synthetic compounds such as chemical synthetic, enzyme synthetic and also natural products or natural products separated and purified.
  • the forms include mineral, salt, oxide, protein complex, complex of protein decomposed product, polysaccharide complex, complex of polysaccharide decomposed product, modified starch complex, cyclodextrin complex or metalloenzyme including minerals such as superoxide dismutase, glutathione peroxidase, acid phosphatase, metal activating enzyme including phosphoglucomutase, enzyme and coenzyme including metal except for active centers.
  • Exemplifying preferred examples of minerals for magnesium group include magnesium carbonate, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium chloride, magnesium oxide, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium hydroxide aluminum, magnesium L-aspartate and magnesium L-glutamate.
  • Magnesium stearate is water insoluble and thus cannot become a source of a mineral. Therefore, the term "diuretically effective mineral" does not include water insoluble magnesium salts such magnesium stearate.
  • Potassium group includes potassium chloride, potassium sulfate, potassium carbonate, potassium dihydrogen citrate, tripotassium citrate, potassium gluconate, potassium acetate, tripotassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium hydroxide, aluminum potassium sulfate, potassium L-aspartate, and monopotassium L-glutamate.
  • Diuretics such as those aminophylline, caffeine, crude drug and herb having diuretic action and minerals etc. can be mixed with one or more than two kinds.
  • daily combination amount of aminophylline is usually between 1 to 400 mg for an adult, preferably between 5 to 350 mg, more preferably between 10 to 300 mg.
  • Daily combination amount of caffeine and anhydrous caffeine is usually between 2 to 900 mg for an adult, preferably between 5 to 700 mg, more preferably between 10 to 500 mg and daily combination amount of "caffeine and sodium benzoate" is usually between 2 to 1800 mg for an adult, preferably between 10 to 1200 mg, more preferably between 10 to 600 mg.
  • Daily combination amount of crude drug and herb having diuretic action is usually between 2 to 18000 mg as crude drug substance for an adult, preferably between 4 to 15000 mg, more preferably between 6 to 12000 mg.
  • Combination amount of mineral is less than 700 mg as magnesium, preferably 1 to 600 mg, more preferably 3 to 500 mg.
  • Potassium is between less than 4000 mg as potassium, preferably 1 to 3000 mg, more preferably 2 to 2000 mg.
  • compositions according to this invention may be administered parentherally, preferably orally in divided doses, most preferably given once a day in the morning, especially before breakfast. Dose adjustment of the active ingredients may reflect age, body weight, and manifesting symptoms.
  • the internal compositions in this invention may also include other active ingredients.
  • the oral dosage form described in this invention can be used in various types of oral forms as tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chew able tablets, troches, effervescent tablets, drops, suspension, oral fast-dispersing tablets, etc.
  • Any of these formulations may be prepared using regular methods, and, in addition to the aforementioned components, any excipients in common use may be used upon preparation of these formulations, if necessary.
  • preparations formed into microparticles such as microcapsules, nanocapsules, microspheres, nanospheres, and included in the aforementioned formulations.
  • the active ingredients i.e.
  • an aqueous extract of red vine leaves and diuretics can be various types of drug forms as separate granules, multi-layer granules, multi-layer tablets or dry coated tablets, tablets of separated granules, microcapsules, etc.
  • Coating preparations such as sugarcoated tablets, film coating tablets, coating granule, can be used as well as chewable tablets, oral fast dispersing tablets, matrix tablets, matrix granules, effervescent tablets, dusting powder, solid solutions, etc. These methods can also be combined.
  • the properties of the inventive internal composition such as stability, release, continuance, disintegration, distinglation, dissolution, concealment of taste, improvement in usage etc. can be regulated by the addition of additives known in the art.
  • oral dosage form described in this invention may be prepared using regular methods by adding generally available pharmaceutical additives and food additives such as excipients, binders, disintegrators, lubricants, coating agents, sugar coating agents, plasticizers, antifoaming agents, polish, foaming agents, antistatic agents, desiccant, surfactant, solubilizer, buffer agents, resolvents, solubilizing agents, solvents, diluents, stabilizers, emulsifying agents, suspension, suspending agents, dispersing agents, isotonizing agents, adsorbents, reducing agents, antioxidant, wetting agents, wet modifier, filler, extender, adhesives, viscous agent, softeners, pH modifiers, antiseptics, preservatives, sweetening agents, corrigent, refrigerative agents, flavoring agents, perfume, fragrance, and coloring matters to the active compounds.
  • food additives such as excipients, binders, disintegrators, lubricants, coating agents, sugar coating agents
  • compositions according to this invention can be provided as pharmaceutical products or foods.
  • the compositions described in this invention are explained by the following practical examples. However, the scope of this invention is not limited to these practical examples.
  • Example 3 Powder The following ingredients were homogeneously mixed. The resulted mixed particles were divided into portions of 1000 mg to prepare powder compositions. Red vine leaves extract 450 g Akebia stem extract 100 g (Akebia stem 2500g) Astragalus root extract 50 g (Astragalus root 500g) Jujube extract 100 g (Jujube 250g) Pyridoxine hydrochloride 50 g Corn starch 124 g Lactose 108 g Light anhydrous silicic acid 10 g Magnesium stearate 8 g

Abstract

This invention relates to a new composition containing the effective dosage of an aqueous extract of red vine leaves (1) and a diuretic (2) for preventing or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs. The compositions according to this invention may also contain pharmaceutically or dietetically acceptable additives.

Description

COMPOSITION COMPRISING AN AQUEOUS EXTRACT OF RED VINE LEAVES AND A DIURETIC FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCES
BACK-GROUND OF THE INVENTION 1. Technical Field The invention relates to compositions comprising an effective dose of an aqueous extract of red vine leaves and a diuretic for preventing or alleviating mild-to-moderate chronic 10 venous insufficiency of the legs. The composition according to this invention also includes acceptable pharmaceutical or dietetic additives. In addition, the compositions according to this inventions decrease or prevent subjective symptoms such as lassitude (listlessness), heavy legs, tired legs, sensation of tension, and pain associated with swelling of calves and ankles due to disorder of leg venous flow. 15 2. Related Art Presently, there are millions of people around the world who suffer from mild-to-moderate chronic venous insufficiency of the legs. This common condition is characterized by an inadequacy of the venous circulation to return blood from the legs to the heart. The lack of 20 adequate venous return results in venous stasis and an increased pressure within the venous circulation, promoting the development of oedema and tissular water retention. Chronic venous insufficiency (CVI) is a functional disorder caused by persistent inadequacy of the venous return and is characterized clinically by oedema, skin changes and subjective complaints such as tired, heavy legs, pain or tingling sensations, which are typically 25 amplified by standing upright and by high ambient temperatures. This dysfunction may be a source of major distress with a significant negative impact on the patient's overall well- being and quality of life.
Early stages (grade I) are characterized by coronal phlebectasia paraplantaris, subfascial 30 congestion and oedema; grade II CVI is associated with low-grade skin changes, eczema and lipodermatosclerosis. If untreated, grades I and II often progress to an advanced stage characterized by recurrent venous leg ulcers (grade HI). The stress caused by the symptoms, even when relatively mild initially, and the risk of later complications call for appropriate supportive and preventive measures to be initiated in the early stages of CVI.
Although some patients, even at early stages, might require surgery (sclerotherapy and variceal surgery), the use of compression stockings with or without additional physiotherapy is the most common treatment approach. The effect of compression is merely mechanical, i.e. this approach does not affect or correct the related biological dysfunction (capillary fragility in particular). Furthermore, the treatment with compression stockings often lacks compliance because of cosmetic concerns and the overall inconvenience of the compressive stockings, in the summer in particular. Therefore there is an urgent need for alternative approaches that are effective, well-tolerated and more convenient.
This extract of red vine leaves contains flavon (ol) -glycosides, -glucuronides and flavonoids, with quercetin-3-O-beta-D-glucuronide and isoquercitrin (quercetin-3-O-beta- glucoside) as its main active ingredients. The range of their pharmacological actions has not yet been fully elucidated, but in- vitro studies indicate that they have antioxidant and anti-inflammatory properties and that they inhibit platelet aggregation and hyaluronidase and reduce oedema, possibly by reducing capillary permeability. Preclinical in-vivo experiments demonstrated anti-inflammatory and capillary wall thickening effects.
Dietary supplements including an aqueous extract of red vine leaves are disclosed to prevent and reduce the discomfort relating to mild-to-moderate chronic venous insufficiency of the legs in WO 01/28363. However, there are no hints to compositions comprising an aqueous extract of red vine leaves and other active ingredients such as diuretics given by WO 01/28363.
SHORT DESCRIPTION OF THE INVENTION Surprisingly, potentiation of anti-inflammatory action and inhibitory action on oedema, indices of pharmacological activities of an aqueous extract of red vine leaves, is found by combination of a diuretic with an aqueous extract of red vine leaves comparing the action itself. Moreover, composing mild diuretics resulted in safe compositions whose efficacy is potentiated for preventing and alleviating discomfort relating to mild-to-moderate chronic venous insufficiency of the legs with minimum or no adverse reactions. The new compositions comprising a diuretic and an aqueous extract of red vine leaves potentiate the efficacy of prevention or relaxation for mild-to-moderate chronic venous insufficiency of the legs.
Therefore, this invention relates to new compositions that comprise an effective dose of an aqueous extract of red vine leaves and a diuretic as pharmacological active substances and their efficacies are potentiated for preventing and relaxing mild-to-moderate chronic venous insufficiency of the legs.
Objective of the present invention
A primary objective of this invention provides more effective internal compositions for preventing and alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
A further objective of this invention provides more effective internal compositions including herb components and a diuretic. The herb components were manufactured pursuant to a controlled process that preserves the herbal effectiveness of the ingredients for preventing and/or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
Another objective of this invention provides more effective internal compositions including herb components and a diuretic with minimum or no adverse event for safety of internal consumption that prevent and/or alleviate the discomfort associated with mild-to- moderate chronic venous insufficiency of the legs. The other objective of this invention provides more effective internal pharmaceutical compositions and foods for preventing and/or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
DETATELED DESCRIPTION OF THE INVENTION
This invention relates to internal compositions for preventing or alleviating the discomfort associated with mild-to-moderate chronic venous insufficiency of the legs including an effective dose of an aqueous extract of red vine leaves and a diuretic.
The internal composition of this invention consists of herbal ingredients derived from an aqueous extraction (Extractum vitis viniferae e folium spissum et siccum) of red vine leaves (folia vitis viniferae) and a diuretic.
The primary active ingredient of the internal composition is the aqueous extract of red vine leaves (foliae vitis viniferae L.).
The term "aqueous extract of red vine leaves" in this invention means the aqueous or solid aqueous extract of red vine leaves manufactured pursuant to a controlled process that preserves the herbal effectiveness of the ingredients. The term "dried extract of red vine leaves" in this invention means dried pure extract of the above aqueous extract of red vine leaves. The term "red vine leaves extract" in this invention means solid extracts added with silicon dioxide in the range of 1 to 10 (wt wt)% (described as %) and glucose syrup (as dried material) in the range of 5 to 25 % to the above dried extract of red vine leaves (solid pure extracts) in the range of 70 to 90 %.
Red vine leaves as starting material for the aqueous extract of red vine leaves in this invention is also known as "dyer" which are leaves of vitis vinifera LINNE with blackish- blue pericarp and a red pulp. Concentration of each polyphenol compound in red vine leaves and its composition are affected by various ecophysiological factors around. It is preferred that dried leaves of red vine containing at least 4 % of total polyphenols and 0.2 % of anthocyans are used as starting material in this invention. Red vine leaves characterized like those are harvested at a point of time where the content of flavonoids has reached an optimum i.e. around the harvesting time of the grapes. Moreover, less than 15 cm length and less than 12 cm width of red vine leaves are preferable. The leaves are carefully dried and crushed. For extraction the leaves are cut to pieces of preferably 5 to 10 mm. To achieve a high content of flavonoids the extraction is done using purified water at elevated temperature, preferably at a temperature in the range of 60 to 80 °C, over a time of at least 6 up to 10 hours. The preferred method is that of an exhaustive percolation. The so-called fluid extract obtained in the process of the extraction may be directly used in the preparation of liquid dosage forms. In order to get a more concentrated extract, at least a part of the solvent is removed by use of a suitable evaporator preferably.
The thick extract is sterilized under heated-compressed condition, preferably at a temperature from 120 to 150°C for 1 up to 30 seconds, more preferably at a temperature from 140 to 145°C for 2 up to 5 seconds. The thick extract obtained in this step may again be directly used in the manufacturing of liquid dosage forms. For the preparation of solid dosage forms the thick extract is dried, for instance by use of a vacuum drying oven or a vacuum drying conveyer. Carriers or excipients may be added during drying to facilitate further processing of the extract.
The ratio of carriers or excipients in the range of 10 to 30 % and dried extract of red vine leaves (as pure extract) in the range of 70 to 90 % in red vine leaves extract is preferable. Such carriers or excipients exemplify one or more than 2 kinds among silicon dioxide, maltodextrine, glucose syrup, cellulose and others. Silicon dioxide and glucose syrup are preferably used in this invention. The ratio of silicon dioxide in the range of 1 to 10 %, glucose syrup (as dried) in the range of 5 to 25 % and dried extract of red vine leaves (as pure extract) in the range of 70 to 90 % in red vine leaves extract is preferable. The ratio of silicon dioxide 2-5 %, glucose syrup (as dried) 10-20 % and dried extract of red vine leaves (as pure extract) 75-85 % in red vine leaves extract is more preferable.
The aqueous extract of red vine leaves used in this invention by pure extract conversion of an aqueous extract of red vine leaves contains total flavonoids (quercetin-3-O-beta-D- glucuronide) preferably in the range of 0.625 to 25 %, more preferably in the range of 1.25 to 12.5 %, specially in the range of 2.5 to 10 %. This total flavonoid (quercetin-3-O-beta- D-glucuronide) content in red vine leaves extract (for example, a case in which dried extract of red vine leaves (as pure extract) 80 %) is preferable from 0.5 to 20 %, more preferable from 1 to 10 , special from 2 to 8 %.
To prevent and/or alleviate the discomfort of mild-to-moderate chronic venous insufficiency of the legs, the daily dosage of the aqueous extract of red vine leaves for an adult in equivalent quantity of dried extract of red vine leaves (pure extract) is usually from 64 to 800mg, preferably from 240 to 640 mg, more preferably from 280 to 600 mg and further more preferably 360 mg. The daily dosage of the aqueous extract of red vine leaves for an adult in equivalent quantity of red vine leaves extract is usually from 80 to lOOOmg, preferably from 300 to 800 mg, more preferably 350 to 750 mg and further more preferably 450 mg.
The compositions according to this invention include diuretics as second active ingredients in addition to above aqueous extract of red vine leaves.
Diuretics used in this invention are not limited and determined if the agents contain diuretic action, however, for safety of this agent with minimum or no adverse event, diuretics with mild effects used in non-prescription drug and health food field for many years are preferable. In addition, types and dosage of diuretics change depending on whether this internal composition is pharmaceutical products or not.
Examples of such diuretics are aminophylline, caffeine, herb and crude drug having diuretics action, and diuretically efficient minerals. Further in detail, caffeine group includes "caffeine and sodium benzoate", anhydrous caffeine, and caffeine etc.
In addition, examples of such crude drug and herb having diuretic action are poria sclerotium (Poria), akebia stem (Akebiae caulis), akebia fruit (Akebiae fructus), astragalus root (Astragali radix), alisma rhizome (Alismatis rhizoma), jujube (Zizyphi fructus), houttuynia herb (Houttuyniae herba), plantago seed (Plantaginis semen), plantago herb (Plantaginis herba), horsetail herb (Equiseti herbά), gardenia fruit (Gardeniae fructus), nettle leaf (Urticae folium), nettle herb (Urticae herba), hibiscus rosell (Hibiscus sabdariffa), anemarrhena rhizome (Anemarrhenae rhizoma), motherwort herb (Leonuri herba), areca husk (Arecae pericarpium), abutilon seed (Abutili semen), campsis flowQv(Campsitis flos), bearberry leaf (Uvae ursi folium), atractylodes lancea rhizome (Atractylodis Lanceae rhizoma), Rice Bean (Phaseoli semen), nuphar rhizome (Nupharis rhizoma), elder (Sambucus sieboldiana blume ex graebn), inula root (Inulae radix), rose fruit (Rosae fructus), sinomenium stem (Sinomeni caulis et rhizoma), hedysarum (Hedysarum polybotrys), magnolia bark (Magnoliae cortex), job's-tears seed (Coicis lacrγma-jobii semen), parslane herb (Portulacae herba), reed rhizome (Phragmitis rhizoma), polyporus (Polyporus umbellatus fries), inula flower (Inulae flos), pharbitis seed (Pharbitidis semen), pumice (Pumex), honeysuckle stem (Lonicerae caulis), pepperweed seed (Lepidii semen), common scouring rush herb (Equiseti herba), physalis rhizome and root (Physalitis rhizoma et radix), kusnezoff monkshood root (Aconiti kusnezofβi radix), Chinese lobelia herb (Lobeliae Chinensis herba), beautiful sweetgum fruit (Liquidambaris fructus), aconite(prepared) (Aconiti carmichaeli praeparata rad), dwarf lilyturf tuber (Ophiopogonis tuber), twotoothed achyranthes root (Achyranthis radix), Chinese waxgourd seed (Benincasae semen), white mulberry root-bark (Mori cortex), loquat leaf (Eriobotryae folium), pucture vine caltrop fruit (Tribuli fructus), natural water-content sodium sulfate (Natrium sulfuricum), elsholtzia herb (Elsholtziae herba), senega (Senegae radix), atractylodes rhizome (Atractylodis rhizoma), lilac pink herb (Dianthi herba), forsythia fruit (Forsythiae fructus), lalang grass rhizome (hnperatae rhizoma), prunellae spica (Prunellae spied), cubeb pepper (Cubebae fructus), corn silk (Maydis stigmata), lightyellow sophora root (Sophorae radix), albizzia bark (Albizziae cortex), belvedere fruit (Kochiae fructus), Chinese iris seed (Iridis semen), evodia fruit (Evodiae fructus), largeleaf gentian root
(Gentianae macrophyllae radix), papermulberry fruit (Broussonetiae fructus), ramie root (Boehmeriae radix), rush (Junci medulla), photinia leaf (Photiniae folium), motherwort fruit (Leonuri fructus), dandelion (Taraxaci herba), sea-ear shell (Haliotidis concha), earthworm (Lumbricus), Japanese raisin tree seed (Hoveniae semen), pyrrosia herb (Pyrrosiae herbά), vaccinium (Vitis-idaea), eupatorium herb (Eupatorii herba), cattail pollen (Typhae pollen), hydrangea (Hydrangea macrophylla), Hyssop (Hyssopus ofβcinalis), wild oat (Avena sativa), parsely (Petroselinum crispum), yarrow (Achillea mϊllefolium), alfalfa (Medicago sativa), garden thyme (Thymus vulgaris), marsh mallow (Althaea ofβcinalis), guarana (Paullinia cupana), cranberry (Vaccinium oxycocos), juniper (Juniperus communis), saw palmetto (Serenoa repens), dandelion (Taraxacum officinale), mate (Ilex paraguayensis), common mallow (Malva sylvestris), linden (Tilia europaea), rose hip (Rosa canina), valerian (Valeriana officinalis), angelica (Angelica archangelica), orange peel (Citrus sinennsis), citrus unshiu peel (Aurantii nobilis pericarpium), celery seed (Apium graveolens), Tarragon (Artemisia dracunculus), chicory (Cichorium intybus), dill seed (Anethum graveolens), parsley (Pertroselinum crispm), meadowsweet (Filipendula ulmaria), linden wood (Tilia cordata), linden flower(7ϊ/ϊα platyphyllos), linden (Tilia europaea), lemon peel(Citrus llimon), Gurmar (Gymnema sylvestre), fennel (Foeniculum vulgare), sweetleaf (Stevia rebaudiana bertoni), chicory (Cichorium intybus), hops (Humulus lupulus), mustard (Sinapis alba), achiote (Bixa orellana), yerba mate (Ilex paraguayensis), mutamba (Guazoma ulmifolia lam.), mullaca (Physalis angulata), perilla (Perilla frutescens), eucommia (Eucommiae cortex), Cha de Burge (Cordia salicifolia), Pearl barley (Coicis fructus), Goldenrod herb (Solidago, Virgaureae herba), Restharrow root (Ononis spinosa radix) and Java tea leaves : cats whiskers (Orthosiphon aristatus) etc. In addition, these crude drug and herb having diuretic action can be dried powder, extract, and fluidextract etc.
Mnerals having diuretic efficacy are any sources of magnesium and potassium. Minerals used in this invention are preferably water soluble synthetic compounds such as chemical synthetic, enzyme synthetic and also natural products or natural products separated and purified. There is no limit for mineral form used in this invention. For example, the forms include mineral, salt, oxide, protein complex, complex of protein decomposed product, polysaccharide complex, complex of polysaccharide decomposed product, modified starch complex, cyclodextrin complex or metalloenzyme including minerals such as superoxide dismutase, glutathione peroxidase, acid phosphatase, metal activating enzyme including phosphoglucomutase, enzyme and coenzyme including metal except for active centers. Exemplifying preferred examples of minerals for magnesium group include magnesium carbonate, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium chloride, magnesium oxide, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium hydroxide aluminum, magnesium L-aspartate and magnesium L-glutamate.
Magnesium stearate is water insoluble and thus cannot become a source of a mineral. Therefore, the term "diuretically effective mineral" does not include water insoluble magnesium salts such magnesium stearate.
Potassium group includes potassium chloride, potassium sulfate, potassium carbonate, potassium dihydrogen citrate, tripotassium citrate, potassium gluconate, potassium acetate, tripotassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, potassium hydroxide, aluminum potassium sulfate, potassium L-aspartate, and monopotassium L-glutamate.
Diuretics such as those aminophylline, caffeine, crude drug and herb having diuretic action and minerals etc. can be mixed with one or more than two kinds.
Combination amount of diuretics used in this invention components changes depend on types of diuretics and categorization as pharmaceutical products or foods, but a daily dose for an adult is between 1 to 18000 mg.
Specifically, daily combination amount of aminophylline is usually between 1 to 400 mg for an adult, preferably between 5 to 350 mg, more preferably between 10 to 300 mg.
Daily combination amount of caffeine and anhydrous caffeine is usually between 2 to 900 mg for an adult, preferably between 5 to 700 mg, more preferably between 10 to 500 mg and daily combination amount of "caffeine and sodium benzoate" is usually between 2 to 1800 mg for an adult, preferably between 10 to 1200 mg, more preferably between 10 to 600 mg. Daily combination amount of crude drug and herb having diuretic action is usually between 2 to 18000 mg as crude drug substance for an adult, preferably between 4 to 15000 mg, more preferably between 6 to 12000 mg.
Combination amount of mineral is less than 700 mg as magnesium, preferably 1 to 600 mg, more preferably 3 to 500 mg. Potassium is between less than 4000 mg as potassium, preferably 1 to 3000 mg, more preferably 2 to 2000 mg.
The compositions according to this invention may be administered parentherally, preferably orally in divided doses, most preferably given once a day in the morning, especially before breakfast. Dose adjustment of the active ingredients may reflect age, body weight, and manifesting symptoms. In addition to active ingredients mentioned above, the internal compositions in this invention may also include other active ingredients.
The oral dosage form described in this invention can be used in various types of oral forms as tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, oral solutions, syrups, dry syrups, chew able tablets, troches, effervescent tablets, drops, suspension, oral fast-dispersing tablets, etc. Any of these formulations may be prepared using regular methods, and, in addition to the aforementioned components, any excipients in common use may be used upon preparation of these formulations, if necessary. In addition, preparations formed into microparticles such as microcapsules, nanocapsules, microspheres, nanospheres, and included in the aforementioned formulations. For example, the active ingredients, i.e. an aqueous extract of red vine leaves and diuretics, can be various types of drug forms as separate granules, multi-layer granules, multi-layer tablets or dry coated tablets, tablets of separated granules, microcapsules, etc. Coating preparations such as sugarcoated tablets, film coating tablets, coating granule, can be used as well as chewable tablets, oral fast dispersing tablets, matrix tablets, matrix granules, effervescent tablets, dusting powder, solid solutions, etc. These methods can also be combined. Moreover, the properties of the inventive internal composition such as stability, release, continuance, disintegration, distinglation, dissolution, concealment of taste, improvement in usage etc. can be regulated by the addition of additives known in the art. These oral dosage form described in this invention may be prepared using regular methods by adding generally available pharmaceutical additives and food additives such as excipients, binders, disintegrators, lubricants, coating agents, sugar coating agents, plasticizers, antifoaming agents, polish, foaming agents, antistatic agents, desiccant, surfactant, solubilizer, buffer agents, resolvents, solubilizing agents, solvents, diluents, stabilizers, emulsifying agents, suspension, suspending agents, dispersing agents, isotonizing agents, adsorbents, reducing agents, antioxidant, wetting agents, wet modifier, filler, extender, adhesives, viscous agent, softeners, pH modifiers, antiseptics, preservatives, sweetening agents, corrigent, refrigerative agents, flavoring agents, perfume, fragrance, and coloring matters to the active compounds. Examples of such additives are described in Japanese Pharmaceutical Excipients Directory 2000 (edited by Japan Pharmaceutical Excipients Council, issued by Yakuji Nippo, Ltd.) and The Japan's Specifications and Standards for Food Additives (issued by Japan Food Additives Association).
The compositions according to this invention can be provided as pharmaceutical products or foods. The compositions described in this invention are explained by the following practical examples. However, the scope of this invention is not limited to these practical examples.
Examples Example 1 Capsules
The following ingredients were prepared as granules through regular methods, and capsule-filled to give an amount of 280 mg per one capsules. Red vine leaves extract 450 g Alisma rhizome extract 50 g (Alisma rhizome 500g) Corn starch 30 g Light anhydrous silicic acid 6 g Talc 18 g Magnesium stearate 6 g
(Red vine leaves extract = dried aqueous extract of red vine leaves (pure extract): silicon dioxide: glucose syrup (as dried glucose)) = 80: 3: 17 wt/wt%)
Example 2
Granules
The following ingredients were prepared as granules through a regular method to prepare mixed particles, and packed to give an amount of 2000 mg per one pack for granules. Red vine leaves extract 225 g Poria sclerotium extract 8 g (Poria sclerotium 240g) Polyporus extract 25 g (Polyporus 250g) Sinomenium stem extract 40 g (Sinomenium stem 500g) Aminophylline 10 g Calcium carboxymethylcellulose 80 g Mannitol 410 g Corn starch 182 g Tartaric acid 8 g Aspartame 8 g Acesulfame potassium 3 g Fragrant materials 1 g
(Red vine leaves extract = dried aqueous extract of red vine leaves (pure extract): silicon dioxide: glucose syrup (as dried glucose)) = 80: 3: 17 wt/wt%)
Example 3 Powder The following ingredients were homogeneously mixed. The resulted mixed particles were divided into portions of 1000 mg to prepare powder compositions. Red vine leaves extract 450 g Akebia stem extract 100 g (Akebia stem 2500g) Astragalus root extract 50 g (Astragalus root 500g) Jujube extract 100 g (Jujube 250g) Pyridoxine hydrochloride 50 g Corn starch 124 g Lactose 108 g Light anhydrous silicic acid 10 g Magnesium stearate 8 g
(Red vine leaves extract = dried aqueous extract of red vine leaves (pure extract): silicon dioxide: glucose syrup (as dried glucose)) = 80: 3: 17 wt/wt%)
Example 4 Tablet
The following ingredients were homogeneously mixed. The resulted mixed particles were compressed with a mold to prepare tablets at 300 mg each. Red vine leaves extract 450 g Anhydrous caffeine 10 g Potassium L-aspartate 20 g Pyridoxine hydrochloride 10 g Lactose 100 g Microcrystalline cellulose 296 g Light anhydrous silicic acid 7 g Magnesium stearate 5 g Talc 2 g (Red vine leaves extract = dried aqueous extract of red vine leaves (pure extract): silicon dioxide: glucose syrup (as dried glucose)) = 80: 3: 17 wt/wt )

Claims

Claims
1. A composition for the prevention and/or alleviation of mild-to-moderate chronic venous insufficiency (CVI) of the legs comprising an aqueous extract of red vine leaves (1) and a diuretic (2) as pharmacologically active substances.
2. A composition according to claim 1 containing an aqueous extract of red vine leaves (1), which is obtained by extraction from dried red vine leaves containing at least 4 % of total polyphenols and at least O.2 % of anthocyans using purified water.
3. A composition according to claim 1 or 2, which contains from 50 to 1000 mg, preferably 64 to 800 mg, in particular about 360 mg or 450 mg of dried aqueous extract of red vine leaves (1).
4. A composition according to any one of claims 1 to 3, which contains from 0.625 to 25 % by weight, preferably from 2.5 and 1O % by weight of flavonoids in the dried aqueous extract of red vine leaves (1).
5. A composition according to any one of claims 1 to 4, which contains dried aqueous extract of red vine leaves (1) and an excipient.
6. A composition according to any one of claims 1 to 5, which contains from 70 and 90 % by weight, preferably 75 to 85 % by weight of dried aqueous extract of red vine leaves (1) and from 10 to 30 % by weight, preferably 10 to 20 % by weight of an excipient.
7. A composition according to any one of claims 1 to 6, which contains 2 to 5 % by weight of silicon dioxide and 10 to 20 % by weight of glucose syrup.
8. A composition according to any one of claims 1 to 7, wherein the diuretic (2) is selected from the group consisting of aminophylline, caffeine, vitamin B6, herb and crude drug including diuretics and a diuretically efficient mineral or a mixture thereof.
9. A composition according to any one of claims 1 and 8, which contains 1 to 18,000 mg of one or more diuretics (2).
10. A composition according to any one of claims 1 and 9, wherein the weight ratio between the dried aqueous extract of red vine leaves (1) to diuretic (2) is from 1 to 1,000 to 1,000 to 1.
11. A composition according to any one of claims 1 and 10, which is suitable for parenteral, preferably oral administration.
12. Use of a composition as claimed in any one of claims 1 to 11 for the preparation of a pharmaceutical product or a health food for the prevention and/or alleviation of mild- to-moderate chronic venous insufficiency (CVI) of the legs.
PCT/EP2004/014458 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences WO2005063270A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0418293-6A BRPI0418293A (en) 2003-12-29 2004-12-18 composition comprising an aqueous extract of red grape vine leaves and a diuretic for the treatment of chronic venous insufficiencies
JP2006546018A JP2007517785A (en) 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red grape leaves and a diuretic for the treatment of chronic venous insufficiency
CA002548357A CA2548357A1 (en) 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences
EP04804059A EP1708729A1 (en) 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences
MXPA06007499A MXPA06007499A (en) 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03029900.2 2003-12-29
EP03029900A EP1550451A1 (en) 2003-12-29 2003-12-29 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiencies

Publications (1)

Publication Number Publication Date
WO2005063270A1 true WO2005063270A1 (en) 2005-07-14

Family

ID=34560172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014458 WO2005063270A1 (en) 2003-12-29 2004-12-18 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences

Country Status (8)

Country Link
US (1) US20050142236A1 (en)
EP (2) EP1550451A1 (en)
JP (1) JP2007517785A (en)
BR (1) BRPI0418293A (en)
CA (1) CA2548357A1 (en)
MX (1) MXPA06007499A (en)
RU (1) RU2006127295A (en)
WO (1) WO2005063270A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001122791A (en) * 1999-10-20 2001-05-08 Boehringer Ingelheim Internatl Gmbh Meal enhancer comprising aqueous extract of red vine leaf for alleviation and prophylaxis of chronic venous insufficiency in lower extremity
EP1550450A1 (en) * 2003-12-29 2005-07-06 Boehringer Ingelheim International GmbH Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies
UA90668C2 (en) * 2004-02-19 2010-05-25 Бёрингер Ингельхайм Интернациональ Гмбх Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent
CA2684601C (en) 2007-04-19 2014-04-29 Mary Kay Inc. Cosmetic methods of treating skin with magnolia and citrus grandis extracts containing compositions
WO2008152624A2 (en) * 2007-06-15 2008-12-18 Antaki Center For Herbal Medicine Ltd Herbal energy-enhancing formulation
JP2011512320A (en) * 2007-08-31 2011-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sprayable composition containing red grape leaf extract
ITTO20070861A1 (en) * 2007-11-29 2009-05-30 Vincenzo Cianni NATURAL FOOD SUPPLEMENT INCLUDING ACTIVE PRINCIPLES OF LEMON FRUIT (CITRUS LIMONUM) AND RED VINE LEAVES (VITIS VINIFERA)
JP4778004B2 (en) * 2008-01-16 2011-09-21 濱野 吉秀 Aoba tea and method for producing the same
DE102008012908A1 (en) * 2008-03-06 2009-09-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the anti-inflammatory and anti-edematous protection of explanted biological material up to its transplantation in patients
RU2563190C2 (en) * 2012-06-14 2015-09-20 Открытое Акционерное Общество "Татхимфармпрераты" Medication based on dry extracts of medicinal plants and method of obtaining thereof (versions)
JP6321908B2 (en) * 2013-02-19 2018-05-09 エスエス製薬株式会社 Oral composition for swelling treatment
WO2014175518A1 (en) * 2013-04-23 2014-10-30 한국식품연구원 Composition for relieving, preventing, or treating pain containing mate extract as active ingredient, and method for evaluating pain relief, prevention, or treatment efficacy of sample
KR101483990B1 (en) 2013-04-23 2015-01-20 한국식품연구원 Method for Evaluating Samples having Effects of Alleviation, Prevention or Treatment for Pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028363A1 (en) * 1999-10-20 2001-04-26 Boehringer Ingelheim International Gmbh Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
WO2003080062A1 (en) * 2002-03-25 2003-10-02 Silvia Perrella Segre Composition comprising vitamin b9, vitamin b6, lipoic acid and plant extracts for treating circulatory disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL278161A (en) * 1961-05-13
JPS55111791A (en) * 1979-02-22 1980-08-28 Japan Synthetic Rubber Co Ltd Antitumor substance
US6210680B1 (en) * 1999-06-11 2001-04-03 Univera Pharmaceuticals, Inc. Method for the prevention and treatment of chronic venous insufficiency
AU5574101A (en) * 2000-04-28 2001-11-12 Univ Emory Decellularized vascular prostheses
US20020192834A1 (en) * 2001-03-23 2002-12-19 Sand Bruce J. Analysis of caffeine
JP4836388B2 (en) * 2002-03-22 2011-12-14 第一三共株式会社 Preventive or therapeutic agent for diseases caused by eNOS expression
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028363A1 (en) * 1999-10-20 2001-04-26 Boehringer Ingelheim International Gmbh Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
WO2003080062A1 (en) * 2002-03-25 2003-10-02 Silvia Perrella Segre Composition comprising vitamin b9, vitamin b6, lipoic acid and plant extracts for treating circulatory disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIESEWETTTER H ET AL: "EFFICACY OF ORALLY ADMINISTERED EXTRACT OF RED VINE LEAF AS 195 (FOLIA VITIS VINIFERAE) IN CHRONIC VENOUS INSUFFICIENCY (STAGES I-II) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 50, no. 2, 2000, pages 109 - 117, XP001146699, ISSN: 0004-4172 *
WUPPERMANN T: "[Chronic venous insufficiency]", DER INTERNIST. JAN 2002, vol. 43, no. 1, January 2002 (2002-01-01), pages 16 , 19 - 26, XP002282786, ISSN: 0020-9554 *

Also Published As

Publication number Publication date
MXPA06007499A (en) 2006-08-31
CA2548357A1 (en) 2005-07-14
US20050142236A1 (en) 2005-06-30
EP1550451A1 (en) 2005-07-06
EP1708729A1 (en) 2006-10-11
JP2007517785A (en) 2007-07-05
RU2006127295A (en) 2008-02-10
BRPI0418293A (en) 2007-05-02

Similar Documents

Publication Publication Date Title
US7422760B2 (en) Plant-based medicament for the treatment of Hepatitis C
CA2551787C (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves and an anti-inflammatory agent
ZA200604097B (en) Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences
US20050142236A1 (en) Composition comprising an aqueous extract of red vine leaves and a diuretic
US20050142235A1 (en) Composition comprising an aqueous extract of red vine leaves and an antithrombotic agent
CN114794478B (en) Composition capable of reducing blood pressure, blood lipid and blood sugar and application
CN107890528B (en) Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof
CN112914097A (en) Health-care solid beverage for damp-heat constitution and preparation method thereof
CN101264172A (en) Preparation of Chinese medicine composition for drug detoxification and application thereof
AU2006200036B8 (en) Vitamin composition, methods and applications
JP2004196750A (en) Stress reliever
JP6321908B2 (en) Oral composition for swelling treatment
CA2438055A1 (en) Treatment of allergic rhinitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004804059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2548357

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006546018

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007499

Country of ref document: MX

Ref document number: 12006501278

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006127295

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004804059

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0418293

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004804059

Country of ref document: EP